Clinical Grip Training and Assessment Tool for Rheumatoid Arthritis

类风湿关节炎的临床握力训练和评估工具

• 批准号: 10050499
• 金额: $ 10.02万
• 依托单位: BAM INNOVATION LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10050499
• 关键词: Clinical; Grip; Training; Assessment; Tool

BAM Innovation and Optima Design will co-design a disruptive treatment and monitoring device for rheumatoid arthritis (RA): Grip-RA.There is a desperate need for alternative approaches to support patients with this incurable autoimmune disease affecting \>23m people worldwide, with one-third of people with RA stopping working within five years of diagnosis and the biologic drugs used to manage the condition being extremely expensive, with dosages needing tailoring based on changes in disease activity.This project will design an innovative device which facilitates patient engagement, monitoring and condition management. Grip-RA is envisaged as a physical "stress-ball" style interface, with embedded sensors, offering gold-standard physical rehabilitation benefits, whilst capturing rich objective and patient-reported data to support better condition management for patients and clinicians. Its simple interface will be intuitive, customer-focused, and accessible, including to those with severe RA. Patients and clinicians are calling out for non-smartphone based approaches, which have notoriously poor patient adherence.BAMs two Directors have a personal interest in RA with deep condition specific knowledge, particularly considering the patient perspective.This project will build on this knowledge to design a new class of rehabilitative tool that links patient and clinical practice in a fashion which offers far clearer benefit to the user.Our main objectives are to research both the commercial pull and design feasibility of the Grip-RA product. We will research potential markets in depth. Close engagement with potential clients will inform us about their needs and inform the design process. This will allow us to produce product designs (CAD + model) driven by customer needs (e.g. clinicians/trusts and pharma) and co-developed/assessed by RA sufferers facilitated by the Bath Institute of Rheumatic Diseases charity.BAM will benefit through being able to enter UK/global RA markets, The global rheumatoid arthritis drugs market is significant, projected to reach $63bn by 2027 and presents multiple opportunities to develop partnerships deploying our technology. An example is our proposed exploratory partnership with a leading clinical home-care/specialist pharmacy provider.Key external beneficiaries are clinicians receiving better patient data and patients themselves, who will receive better rehabilitation/treatment reducing suffering and supporting better engagement with society and the economy.

BAM Innovation 和 Optima Design 将共同设计一种治疗类风湿性关节炎 (RA) 的颠覆性治疗和监测设备：Grip-RA。这种无法治愈的自身免疫性疾病影响着全球超过 2300 万人，迫切需要替代方法来支持患者。三分之一的 RA 患者在诊断后五年内停止工作，用于控制病情的生物药物非常昂贵，剂量需要根据疾病活动的变化进行调整。该项目将设计一种创新设备，促进患者参与、监测和病情管理。 Grip-RA 被设想为物理“压力球”式界面，带有嵌入式传感器，提供黄金标准的物理康复益处，同时捕获丰富的客观和患者报告的数据，以支持患者和临床医生更好的病情管理。其简单的界面直观、以客户为中心且易于使用，包括那些患有严重 RA 的人。患一种新型的康复工具，以一种为用户提供更明显利益的方式将患者和临床实践联系起来。我们的主要目标是研究 Grip-RA 产品的商业吸引力和设计可行性。我们将深入研究潜在市场。与潜在客户的密切接触将使我们了解他们的需求并为设计过程提供信息。这将使我们能够根据客户需求（例如临床医生/信托机构和制药公司）生产产品设计（CAD + 模型），并由巴斯风湿病研究所慈善机构协助的 RA 患者共同开发/评估。BAM 将受益于能够为了进入英国/全球 RA 市场，全球类风湿关节炎药物市场规模巨大，预计到 2027 年将达到 630 亿美元，并提供了多种机会来发展部署我们技术的合作伙伴关系。一个例子是我们提议与一家领先的临床家庭护理/专业药房提供商建立探索性合作伙伴关系。主要的外部受益者是获得更好患者数据的临床医生和患者本身，他们将获得更好的康复/治疗，减少痛苦并支持更好地参与社会和经济。